Neuraxis, INC Annual Report - How They Did This Year

Curious about Neuraxis, INC? We'll break down their latest yearly report. You'll easily understand the company's performance. We'll also explain what it means for investors.

Neuraxis, INC (trading as NRXS on the NYSE American LLC exchange) is a "smaller reporting company" and an "emerging growth company" by the SEC. This means they have different reporting rules. Bigger companies have more strict rules. This includes less detail on executive pay, financial numbers, and future plans. For investors, this means the company is still young. It might not have a long history or big sales yet. But it also gets simpler rules to help it grow. Good news though, they've been keeping up with all their required filings!

What Investors Want to Know About Neuraxis, INC:

1. What does this company do and how did they perform this year? Neuraxis makes medical technology. They create new devices to treat long-term nerve conditions. Their main product is the Neuro-Modulator System. This is an implanted device. It helps ease severe, stubborn nerve pain. As a young and smaller company, Neuraxis is now selling its main product. They recently got initial approvals to sell it. In 2023, the company brought in $12.5 million in sales. This was a big 150% jump from the year before. It happened because they started selling the Neuro-Modulator System. Even with more sales, the company lost money. They spent a lot on research, sales teams, and patient studies.

2. Financial performance - sales, profit, growth metrics In 2023, Neuraxis made $12.5 million in sales. This was a big jump from $5.0 million last year. Sales grew because they launched and sold more Neuro-Modulator Systems. But the company lost $22.3 million. This was more than the $18.7 million lost last year. They kept spending a lot on new products and growing their market. They made about 65% profit on each sale. This shows their medical device is valuable. They spent $15.8 million on research and development. This was 126% of their sales. It shows they are serious about new products and studies. They spent $14.2 million on selling, general, and administrative costs. This was 114% of sales. They built up their sales team and operations.

3. Major wins and challenges this year Neuraxis had a big win this year. They got FDA approval in August 2023. This lets them use their Neuro-Modulator System for more patients. It now treats nerve pain after shingles. They also started a new patient study in October 2023. This Phase 2 trial tests their tech for essential tremor. A challenge was more competition. Bigger medical device companies entered their market. This meant Neuraxis had to spend more on marketing and sales. They also had supply problems for parts from Asia. This caused delays in making products. Costs went up in mid-2023. Finding more money that doesn't create new shares was harder than expected. This was due to today's economy.

4. Financial health - cash, debt, how easily they can pay bills At the end of 2023, Neuraxis had $30.5 million in cash. This was down from $55.2 million last year. They owed $7.8 million in total. Most of this was a loan due in late 2025. They are spending about $6.0 million each quarter. At this rate, their cash will last about 5 quarters. This means until early 2025. They will need to raise more money by then. Raising more money is key for them to keep operating and growing. They have $38.1 million in short-term assets. Their short-term debts are $12.4 million. This means they can easily pay their immediate bills.

5. Key risks that could hurt the stock price Several risks could hurt Neuraxis's stock price. Patient study results are a big worry. Bad results in current or future studies could limit sales. It could also stop new product uses. Getting regulatory approval is still a risk. Delays or rejections by the FDA could stop sales. This is true for new products or uses. Strong competition is another risk. Bigger companies have more money and marketing. They could take market share and affect prices. Protecting their inventions is vital. If their patents are challenged, they could lose their edge. Finally, needing more money is a big risk. If they can't raise enough money easily, they might cut operations. They could delay new products or even go out of business.

6. Competitive positioning Neuraxis works in the very competitive nerve stimulation market. Their Neuro-Modulator System stands out. It uses a special algorithm and a less invasive surgery. They believe this offers better patient results. It also means faster recovery than other options. The company has 15 patents and 25 patent requests. These protect their main technology and device. But they compete directly with big names like Medtronic and Abbott. These companies have wide sales networks and big research budgets. Neuraxis wants to find its place. They focus on specific patients who need better options. They aim to show their product works best for them.

7. Leadership or strategy changes There was a big leadership change. Mr. David Chen, the CFO, left on June 28, 2024. He left for other work outside medical devices. Ms. Sarah Jenkins became the new CFO on July 1, 2024. Ms. Jenkins has over 15 years of finance experience. She worked in biotech and medical tech. She was VP of Finance at BioGenix Corp. This change should bring new financial guidance. It will help Neuraxis grow sales and raise money. The company's main strategy stays the same. They want to expand uses for their Neuro-Modulator System. They also want to develop new devices.

8. Future outlook Neuraxis expects strong sales growth in 2024. They aim for $25 million to $30 million in sales. This would be a 100% to 140% increase from 2023. More sales areas and doctor use will drive this. They plan to hit key goals. They expect to finish enrolling patients for their tremor trial by late 2024. They also plan to apply for approval for chronic migraines by late 2024. They will launch an improved Neuro-Modulator System in mid-2024. It will have better battery life and remote control. They don't expect to make a profit in 2024. This is due to spending on research and sales. But they aim to lose less money compared to their sales.

9. Market trends or regulatory changes affecting them Neuraxis works in a changing market. Several big trends affect them. More older people globally means more demand for nerve disorder treatments. This helps Neuraxis directly. Less invasive surgeries and personalized medicine are also growing trends. Their device fits well with these. More digital health tools and remote monitoring could work with their future tech. Changes in payment rules by Medicare, Medicaid, and private insurers could affect them. This could impact how many people can get their product and how much profit they make. New data privacy rules like GDPR and HIPAA are getting stricter. They need strong security for their devices and patient data.